论文部分内容阅读
目的研究厄洛替尼对非小细胞肺癌(NSCLC)脑转移细胞PC14/B侵袭转移能力的抑制作用。方法 PC14/B细胞随机分为对照组及3个浓度实验组(厄洛替尼,1,5,25μmol·L~(-1)),噻唑蓝法和迁移小室法分别检测细胞活力及侵袭能力,免疫印迹法检测基质金属蛋白酶2(MMP2)、MMP9、上皮细胞-间充质转化(EMT)相关蛋白E-钙黏附素、波形蛋白的表达及蛋白激酶B(AKT)磷酸化水平。结果与对照组(0.75±0.09)比较,小中大3个浓度实验组均能显著抑制PC14/B细胞活力,比值分别为(0.63±0.06),(0.52±0.04),(0.38±0.03)。与对照组比较,3个浓度实验组均能显著降低侵袭力,上调E-钙黏附素表达,下调MMP2、MMP9及波形蛋白表达,并降低AKT磷酸化水平。结论厄洛替尼能显著的抑制PC14/B细胞侵袭转移能力,与下调MMPs表达、抑制EMT生成及降低AKT磷酸化水平有关。
Objective To investigate the inhibitory effect of erlotinib on the invasion and metastasis of PC14 / B cells in non-small cell lung cancer (NSCLC). Methods PC14 / B cells were randomly divided into control group and three concentrations of experimental group (erlotinib, 1,5,25μmol·L -1), cell viability and invasion ability were detected by MTT method and migration chamber method The expressions of MMP2, MMP9, EMT related protein E-cadherin, vimentin and phosphorylation of protein kinase B (AKT) were detected by Western blotting. Results Compared with the control group (0.75 ± 0.09), the experimental groups at three concentrations of small, medium and large could significantly inhibit the viability of PC14 / B cells. The ratios were (0.63 ± 0.06), (0.52 ± 0.04) and (0.38 ± 0.03), respectively. Compared with the control group, the three concentrations of the experimental group can significantly reduce invasiveness, upregulation of E-cadherin, down-regulation of MMP2, MMP9 and vimentin expression, and reduce the phosphorylation of AKT levels. Conclusion Erlotinib can significantly inhibit the invasion and metastasis of PC14 / B cells, which is related to down-regulating the expression of MMPs, inhibiting the production of EMT and decreasing the phosphorylation of AKT.